1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Takasago International Corporation

Takasago International Corporation

4914.T
Takasago International CorporationJP flagTokyo Stock Exchange
1,160.00
JPY
+3.00
- -
113.10BMarket Cap
Takasago International Corporation
4914.T
(Tokyo Stock Exchange)

Recent

price

1,160.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,144.42
1,137.74
1,198.5
1,320.7
1,327.28
1,428.24
1,381.66
1,434.64
1,524.52
1,552.02
1,533.5
1,655.27
1,902.91
2,013.29
2,352.76
2,309.29
1,000.06
Revenue per Share
39.69
17.76
47.07
30.49
25.7
49.2
63.92
70.93
48.33
34.69
72.96
90.78
75.32
27.72
136.78
97.72
5.81
Basic EPS, GAAP
41.14
31.39
-3.43
-32.94
-31.06
-26.84
78.84
25.3
10.31
-62.78
69.12
35.84
-6
23.95
68.01
-174.32
- -
Free Cash Flow per Basic Share
8.99
8.04
7.99
7.99
7.99
8.01
9.01
9.99
11
11
12.98
11
13.98
15.99
22.95
55.9
- -
Dividend per Share
477.67
489.56
531.82
554.59
570.44
612.67
669.07
731.97
769.05
796.64
858.03
937.57
998.62
1,018.94
1,131.81
1,173.03
1,061.87
Book Value per Share
488.98
499.54
592.94
694.6
788.5
802.89
860.92
979.45
975.05
951.5
1,013.17
1,094.71
1,201.73
1,296.37
1,452.16
1,544.44
1,419.7
Tangible Book Value per Share
100
100
99
99
99
99
99
99
99
98
98
98
98
97
97
97
97
Basic Weighted Avg Shares
114,861
113,676
118,973
131,036
131,653
141,660
136,764
141,592
150,516
152,455
150,367
162,440
186,792
195,940
229,207
225,092
97,368
Sales/Revenue/Turnover
5.15
3.49
5.28
4.12
2.39
4.68
5.23
4.49
3.88
1.75
4.18
5.42
3.18
1.18
6.69
3.61
0.81
Operating Margin (%)
5,254
4,895
4,619
4,770
5,277
4,815
5,422
5,792
6,196
6,495
6,554
6,912
7,378
7,860
8,114
8,756
- -
Depreciation Expense
3,984
1,774
4,673
3,025
2,549
4,880
6,327
7,000
4,772
3,408
7,154
8,909
7,393
2,698
13,325
9,525
566
Net Income, GAAP
28.11
53.52
33.71
32.85
43.96
24.8
18.9
- -
29.39
24.09
15.36
17.19
11.82
42.52
22.83
26.18
53.53
Effective Tax Rate (%)
3.47
1.56
3.93
2.31
1.94
3.44
4.63
4.94
3.17
2.24
4.76
5.48
3.96
1.38
5.81
4.23
0.58
Profit Margin (%)
21,763
22,106
27,678
32,740
32,164
36,002
39,989
39,099
41,369
35,510
41,384
49,777
55,908
56,970
74,641
69,341
64,671
Working Capital
13,806
12,527
14,088
18,731
22,987
29,105
28,935
24,623
22,012
19,377
18,902
16,919
14,970
15,579
22,194
22,435
15,001
LT Debt
52,637
52,837
61,295
71,109
80,048
81,611
87,209
98,401
97,395
94,773
101,346
110,294
121,951
130,877
146,392
156,049
142,829
Total Equity
4.54
2.02
4.33
3.29
1.38
3.61
4.13
- -
2.78
1.38
3.65
4.84
3.25
0.76
6.06
2.79
0.2
Return on Invested Capital (%)
4.83
2.09
5.32
3.19
2.38
4.28
5.47
- -
4.11
2.96
5.77
6.83
5.43
1.97
8.39
5.43
0.46
Return on Capital (%)
8.59
3.66
9.19
5.61
4.57
8.32
9.96
10.11
6.44
4.42
8.81
10.12
7.78
2.74
12.73
8.48
0.56
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
33,408
- -
30,880
LT Borrowings
13,327
- -
15,001
LT Finance Leases
2,252
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
- -
97
Market Capitalization
67,314
76,624
107,293

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
126,038
- -
135,100
Cash, Cash Equivalents & STI
18,333
- -
11,172
Accounts Receivable, Net
45,567
- -
57,865
Inventories
55,455
- -
58,435
Total Current Liabilities
69,068
- -
70,429
Payables & Accruals
- -
- -
- -
ST Debt
33,408
- -
30,880
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.81%
9.03%
6.6%
Free Cash Flow
-226.89%
-166.56%
-356.43%
Net Income, GAAP
39.92%
61.87%
-28.52%
Sales/Revenue/Turnover
4.94%
8.62%
-1.8%
Total Cash Common Dividend
26.3%
42.54%
143.69%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48,532
50,040
50,000
47,368
195,940
2025
- -
- -
- -
- -
229,207
2026
- -
- -
- -
- -
225,092

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10.49
- -
- -
- -
27.72
2025
- -
- -
- -
- -
136.78
2026
- -
- -
- -
- -
97.72

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
15.99
2025
- -
- -
- -
- -
22.95
2026
- -
- -
- -
- -
55.9
Similar Companies
Incitec Pivot Limited (INCZY)
Vikas Lifecare Limited (VIKASLIFE.BO)
Plásticos Compuestos, S.A. (ALKOM.PA)
Anhui Guangxin Agrochemical Co., Ltd. (603599.SS)
Balchem Corp (BCPC)
Hindustan Fluorocarbons Limited (HINFLUR.BO)
Business
Takasago International Corporation (4914.T) manufactures and markets flavors, fragrances, aroma chemicals and functional ingredients for the food, beverage, cosmetics, pharmaceuticals and household products industries worldwide. The company produces natural and synthetic flavors including fruit, dairy, savory and beverage profiles; synthetic and natural fragrances for fine, personal care and household applications; aroma chemicals such as musks, aldehydes and esters; and functional ingredients like masking agents and natural extracts. Takasago offers custom formulation services, fragrance compounding and application development through its global research and development network. Founded in 1920 and headquartered in Tokyo, Japan, Takasago operates production facilities and sales offices across North America, Europe, Asia-Pacific and Latin America, serving multinational consumer goods companies and regional brands in the flavor and fragrance sector. The company segments its business into flavors for food and beverages; fragrances for perfumes, soaps, detergents and air care products; and advanced aroma solutions for health and wellness applications. Subsidiaries include Takasago USA, Inc. and Takasago Europe GmbH, with no parent company affiliation. In the last two years, Takasago expanded its sustainable ingredient portfolio through a strategic partnership with Givaudan for biotech-derived aroma compounds and completed the acquisition of a natural extracts facility in France to bolster organic flavor capabilities. The company launched its BioPure line of fermentation-based flavors in 2024 and secured a major funding round from institutional investors to advance biotech R&D. Takasago also reorganized its Asia-Pacific operations for enhanced supply chain efficiency amid global demand growth.